Cannabinoid–Opioid Interaction in Chronic Pain

@article{Abrams2011CannabinoidOpioidII,
  title={Cannabinoid–Opioid Interaction in Chronic Pain},
  author={Donald I. Abrams and Paul Couey and Starley B. Shade and Mary Ellen Kelly and Neal L. Benowitz},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2011},
  volume={90}
}
Cannabinoids and opioids share several pharmacologic properties and may act synergistically. The potential pharmacokinetics and the safety of the combination in humans are unknown. We therefore undertook a study to answer these questions. Twenty–one individuals with chronic pain, on a regimen of twice–daily doses of sustained–release morphine or oxycodone were enrolled in the study and admitted for a 5–day inpatient stay. Participants were asked to inhale vaporized cannabis in the evening of… 
The Role of Cannabinoids in Chronic Pain Patients Remains Hazy
TLDR
This study fails to demonstrate a clear synergistic effect in pain control as was concluded by the authors, and further studies are necessary to evaluate analgesia in relation to cannabis exposure in opioid-dependent patients.
Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans
TLDR
It is suggested that dronabinol may not be an effective or appropriate opioid adjuvant; it could potentially increase opioid dose requirements, while increasing psychoactive opioid effects.
Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability
TLDR
Cannabis enhances the analgesic effects of sub-threshold oxycodone, suggesting synergy, without increases in cannabis’s abuse liability, which supports future research into the therapeutic use of opioid-cannabinoid combinations for pain.
Cannabinoids, Pain, and Opioid Use Reduction: The Importance of Distilling and Disseminating Existing Data.
TLDR
This article provides a set of guidelines on how to approach using cannabis to treat pain, and demonstrates that a combination of Δ9-tetrahydrocannabinol and cannabidiol has low potential for harm, is well tolerated, and is helpful to patients.
Antinociceptive and Abuse Potential Effects of Cannabinoid/Opioid Combinations in a Chronic Pain Model in Rats
TLDR
Combining CP55940 with morphine, but not tramadol, shows a better antinociceptive profile with no additional risk of abuse liability, which represents a potential pain management approach.
Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies
TLDR
Preclinical and observational studies demonstrate the potential opioid- Sparing effects of cannabinoids in the context of analgesia, in contrast to higher-quality RCTs that did not provide evidence of opioid-sparing effects.
The Pharmacokinetics, Efficacy, Safety, and Ease of Use of a Novel Portable Metered-Dose Cannabis Inhaler in Patients With Chronic Neuropathic Pain: A Phase 1a Study
TLDR
The potential use of the Syqe Inhaler device as a smokeless delivery system of medicinal cannabis, producing a Δ9-THC pharmacokinetic profile with low interindividual variation of Cmax, achieving pharmaceutical standards for inhaled drugs is suggested.
Challenges and Opportunities in Preclinical Research of Synthetic Cannabinoids for Pain Therapy
TLDR
Synthetic cannabinoids are one of the most promising classes of drugs in pain medicine, and preclinical research should focus on identifying new and improved alternatives for a better clinical and pre clinical outcome.
Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis
TLDR
Pre-clinical studies provide robust evidence of the opioid-sparing effect of cannabinoids, whereas one of the nine clinical studies identified provided very-low-quality evidence of such an effect.
...
...

References

SHOWING 1-10 OF 54 REFERENCES
Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy.
Short-Term Effects of Cannabinoids in Patients with HIV-1 Infection
TLDR
The findings of no large harmful effects on viral loads with either smoked or oral cannabinoids need to be confirmed in larger and longer trials, and the likelihood of a drugdrug interaction between protease inhibitors and marijuana is worrisome since many HIV-infected patients continue to smoke marijuana as an appetite stimulant or to decrease nausea associated with their antiretroviral therapy.
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
TLDR
Coadministration of medicinal cannabis, as herbal tea, in cancer patients treated with irinotecan or docetaxel does not significantly influence the plasma pharmacokinetic parameters with and without concomitant medicinal cannabis.
Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy
TLDR
Control-release (CR) oxycodone has become one of the most frequently utilized sustained-release opioids in the United States and both its analgesic benefits and its side effects are similar to those of CR morphine.
...
...